The relative importance of set and setting suggests that the environment in an LSD experience should be carefully controlled.
I think the problem is I have read the research, and it didn’t confirm the claims made on its behalf.
The increased incidence of depression, anxiety, and other psychiatric symptoms linked to OUD may also help to account for high rates of relapse among patients, post-treatment, versus other substance disorders.
These are questions that come up with every drug, not just cannabis. And unanswered, they can lead to problems down the road.
The public , including those in elected office, seem to assume that the expected prohibition on sales and use by underage persons will somehow be enough to limit the damage.
The field is getting accustomed to patients arriving in addiction treatment complaining of problems with prescription opioids, stimulants, sedatives, etc, while actively enrolled in medical cannabis programs.
More likely the hope is to increase awareness of the risks, and encourage drinkers to limit consumption.
The goal is to eventually develop an objective scale by which pain can be measured not by self-report, but by neuroimaging.
My concern is that these same hallucinogens have a pronounced tendency to escape the research environment and find their way out into the streets